Corrigendum to “In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways”

• Erik Skoglund,
• Henrietta Abodakpi,
• Rafael Rios,
• Lorena Diaz,
• Elsa De La Cadena,
• An Q. Dinh,
• Javier Ardila,
• William R. Miller,
• Jose M. Munita,
• Cesar A. Arias,
• Vincent H. Tam,
• Truc T. Tran

Affiliations

Erik Skoglund

University of Houston College of Pharmacy, Houston, TX, USA

Henrietta Abodakpi

University of Houston College of Pharmacy, Houston, TX, USA

Rafael Rios

Molecular Genetics and Antimicrobial Resistance Unit, International Center for Microbial Genomics, Universidad El Bosque, Bogotá, Colombia

Lorena Diaz

Molecular Genetics and Antimicrobial Resistance Unit, International Center for Microbial Genomics, Universidad El Bosque, Bogotá, Colombia

Elsa De La Cadena

Grupo de Investigación en Resistencia Antimicrobiana y Epidemiología Hospitalaria–RAEH, Universidad El Bosque, Bogotá, Colombia

An Q. Dinh

Center for Antimicrobial Resistance and Microbial Genomics, UTHealth McGovern Medical School, Houston, TX, USA

Javier Ardila

Molecular Genetics and Antimicrobial Resistance Unit, International Center for Microbial Genomics, Universidad El Bosque, Bogotá, Colombia

William R. Miller

Center for Antimicrobial Resistance and Microbial Genomics, UTHealth McGovern Medical School, Houston, TX, USA

Jose M. Munita

Center for Antimicrobial Resistance and Microbial Genomics, UTHealth McGovern Medical School, Houston, TX, USA

Cesar A. Arias

Molecular Genetics and Antimicrobial Resistance Unit, International Center for Microbial Genomics, Universidad El Bosque, Bogotá, Colombia

Vincent H. Tam

University of Houston College of Pharmacy, Houston, TX, USA

Truc T. Tran

Center for Antimicrobial Resistance and Microbial Genomics, UTHealth McGovern Medical School, Houston, TX, USA